US$ 26.68
glp 1 agonist in pregnancy Continuation of GLP-1 Receptor Early Seems Safe Continuing Glucagon-Like Peptide-1 Receptor Agonists
Description
optimizing your clinical trials

Efficacy and safety of iGlarLixi, fixed-ratio combination of insulin glargine and lixisenatide, compared with basal-bolus regimen in patients with type 2 diabetes: propensity score matched analysis
The REWIND trial with dulaglutide and SUSTAIN-6 with semaglutide also demonstrated cardiovascular benefits

It plays a pivotal role in energy balance and postprandial metabolism by enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety through central mechanisms [8, 9]

NPJ Parkinsons Dis (2020) 6:15
